Article info
PDFLetter
COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD
- Correspondence to Dr Oliver Distler, Department of Rheumatology, University Hospital Zurich, Zurich 8091, Switzerland; oliver.distler{at}usz.ch
Citation
COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD
Publication history
- Received March 27, 2020
- Accepted March 30, 2020
- First published April 2, 2020.
Online issue publication
April 12, 2023
Article Versions
- Previous version (13 May 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.
https://bmj.com/coronavirus/usage